

Konwave ATG Global Healthcare

Factsheet September 2026 - as of 30.09.2026

This document is a marketing communication



FUND DESCRIPTION

Investment Objective:

The Fund aims to achieve long-term capital growth by investing in equities of companies in the global healthcare sector. The Fund seeks to outperform its benchmark over rolling three- and five-year periods.

Philosophy:

The Fund applies a disciplined bottom-up investment approach based on the GARP philosophy (Growth at a Reasonable Price), combining attractive growth prospects with reasonable valuations. The portfolio focuses on listed mid- and large-cap healthcare companies worldwide. ESG considerations are fully integrated into the investment process to support responsible and sustainable investment decisions.

Investment Strategy:


The Fund invests globally across developed and emerging markets, including the Asia-Pacific region, in healthcare-related industries such as pharmaceuticals, biotechnology, medical technology, and healthcare services.

The Investment Manager seeks companies with strong financial fundamentals, sustainable competitive advantages, and experienced management teams, whose valuations offer attractive risk-adjusted return potential. Risk management is embedded throughout security selection and portfolio construction, with an emphasis on capital preservation alongside return generation.


MONTHLY PERFORMANCE

	Jan 26	Feb 26	Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	Sep 26	YTD
USD -F-										
Konwave ATG Global HC	0,61%	2,49%	-7,32%	-0,54%	0,48%	3,62%	-0,77%	5,01%	-0,37%	2,73%
MSCI Global HC	0,65%	2,89%	-8,28%	-0,24%	1,92%	5,00%	1,45%	3,71%	-1,79%	4,77%

REGIONAL ALLOCATION



SECTOR ALLOCATION



Konwave ATG Global Healthcare

Factsheet September 2026 - as of 30.09.2026

This document is a marketing communication



FUND DATA

NAV/ISIN/Sedol USD F ACC	USD 101,83	IE000SORA239/BW2FJT8	Type	Open end
ISIN USD I ACC		IE000ADTCID5	Domicile	Ireland
ISIN CHF I ACC		IE0009AIPZQ3	SFDR Classification	Article 8
ISIN EUR I ACC		IE000BSKMWW0	Custodian	Northern Trust International Fund Administration
ISIN CHF Q ACC		IE0000PQA7A7	Fund Mgmt	
			Company	Harrington Cooper UCITS Funds ICAV
			Investment	
			Manager	ATG Healthcare Investments AG
			Auditor	Deloitte Ireland
			Management fee	0,6%-0,8%* p.a. (F) / 0,9% p.a. (I) / 1,5% p.a. (Q)
			Adm. / Custody fee	ca. 0,2%** p.a.
			Pricing / Cut-Off	Daily / 12:00 Noon (Ireland)
			Issue fee	0%
			Redemption fee	0%

* Depending on Fund Size

** Estimate

TOP-TEN HOLDINGS

COMPANY	COUNTRY	WEIGHT
AbbVie	United States	5,6%
Eli Lilly	United States	5,5%
J&J	United States	5,0%
Merck	United States	4,3%
AstraZeneca	United Kingdom	3,8%
Roche	Switzerland	3,6%
Thermo Fisher	United States	3,1%
Vertex	United States	3,0%
Argenx	Belgium	3,0%
Edwards	United States	2,9%

STATISTICAL DATA (USD -F-)

Annualised return	n.a.
Return since inception*	2,73%
Inception date	04/12/2025
Volatility	n.a.
Information ratio	n.a.
Tracking error	n.a.
Fund size (all share classes)	USD 147,7mn

* Performance inception as of 30/12/2025

Important notes: The information on this document should be considered non-independent as Harrington Cooper LLP and Harrington Cooper Asset Management Limited have been retained by ATG Healthcare Investments AG for the promotion of the strategies and funds to professional investors in the United Kingdom and the European Union. This document does not constitute or form part of any offer to issue or sell, or any solicitation by Harrington Cooper LLP, Harrington Cooper Asset Management Limited, ATG Healthcare Investments AG or any of their affiliates, of any offer to subscribe or purchase any securities mentioned herein. The information in this document should not be construed as the making of a personal recommendation or the giving of investment advice or recommending the undertaking of any investment activity either within or outside the United Kingdom. No investment decisions should be made without first reviewing the prospectus for the Harrington Cooper UCITS Funds ICAV in conjunction with the fund supplement and the PRIIPS KID/UCITS KIID for the share class, a summary of the investor rights and any other supplementary information, which can be obtained free of charge from <http://harringtoncooper.com/harrington-cooperasset-management-funds/>. The Prospectus and supplements for the fund are available in English. The PRIIPS KID and UCITS KIID as applicable are available in English. Where required under national rules, the key information document will also be available in the local language of the relevant EEA Member State. A decision may be taken at any time to terminate the arrangements made for the marketing of the Funds on the Harrington Cooper UCITS Funds ICAV in any EEA Member State in which it is currently marketed. In such circumstances, Shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the Fund free of any charges or deductions for at least 30 working days from the date of such notification. The value of all investments and any income derived therefrom can decrease as well as increase and capital may be lost. This information is not for use within any country or with respect to any person(s) where such use could constitute a violation of the applicable law. This document is only for professional clients or eligible counterparties (or such persons whom it may lawfully be issued or directed) In particular, any investment or services to which this document may relate are not intended for retail clients and will not be made available to retail clients. No representation, warranty or undertaking, expressed or implied, is given as to the accuracy, timeliness or completeness of the information and no liability is accepted by Harrington Cooper LLP or Harrington Cooper Asset Management Limited or ATG Healthcare Investments AG or their affiliates for the information or opinions contained in this document. Management company and distributor (European Union): Harrington Cooper Asset Management Limited, which is regulated by the Central Bank of Ireland. Registered office: Block A, One Park Place, Upper Hatch Street, Dublin 2, Ireland. Harrington Cooper UCITS Funds ICAV is authorised and regulated by the Central Bank of Ireland. Distributor (UK): Harrington Cooper LLP, which is authorised and regulated by the Financial Conduct Authority, is a Limited Liability Partnership registered in England and Wales under registration number OC319697. Registered office: The Royal Exchange, 2 Royal Exchange Steps, London, EC3V 3DG, United Kingdom. Telephone: +44 0 207 043 0500.